Posted inBiotechnology
Ozone Therapy: Revitalizing Recovery in Sepsis-Induced Lung Injury
In a groundbreaking advancement in the fight against sepsis-induced acute lung injury (ALI), researchers have identified medical ozone therapy as…
Posted inBiotechnology
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Posted inBiotechnology
Fierce Biotech Fundraising Tracker ’25: Orbis rings in new year with €90M series A
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled…
Posted inBiotechnology
Fierce Biotech Layoff Tracker 2025: CytomX cuts team by 40%
We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared…
Posted inBiotechnology
Ikena, after tough year of layoffs, merges with Inmagene to focus on phase 2 dermatitis prospect
After a year that saw Ikena Oncology trim back its workforce and pipeline, the oncology biotech thinks it has found…
Posted inBiotechnology
Rapt re-rolls after flameout, paying $35M for challenger to Novartis, Roche drug
Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a…
Posted inBiotechnology
Sanofi pays SK bioscience €50M as children’s pneumococcal vaccine enters phase 3
Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal conjugate vaccine…
Posted inBiotechnology
Phase 2 data will drive biopharma VC investments next year: PitchBook
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into…
Posted inBiotechnology
Discover Astellas’ differentiated approach to innovation partnerships
As a global life sciences company, Astellas is passionate about partnering to advance life-changing treatments for patients. If you are…
Posted inBiotechnology
Galectin’s MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Galectin Therapeutics’ stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people…